ArticleIJU case reports2026
Primary Pure Yolk Sac Tumor of the Urinary Bladder: A Case Report.
Article in IJU case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Yolk sac tumors are malignant germ cell tumors that typically arise in the gonads. Although extragonadal cases have been reported, primary involvement of the urinary tract is extremely rare. Case Presentation: A 67-year-old man presented with gross hematuria. Cystoscopy and contrast-enhanced computed tomography revealed a 6-cm bladder mass. Transurethral resection of the bladder tumor was performed. Histopathological and immunohistochemical findings (alpha-fetoprotein, glypican-3, and Sal-like protein 4 positivity) were consistent with a yolk sac tumor without a urothelial carcinoma component. Additional examinations revealed no primary lesions elsewhere, leading to the diagnosis of a primary bladder yolk sac tumor. The patient received four cycles of etoposide and cisplatin chemotherapy and has remained recurrence-free for 2 years. Conclusions: Patients with primary bladder yolk sac tumors, although rare, may achieve favorable outcomes with combined surgical resection and chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.